Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nineteen have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $298.61.
Several equities research analysts have commented on ALNY shares. Raymond James boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Scotiabank boosted their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Sanford C. Bernstein dropped their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st.
Read Our Latest Analysis on ALNY
Alnylam Pharmaceuticals Trading Down 1.9 %
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The firm’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 EPS. Sell-side analysts anticipate that Alnylam Pharmaceuticals will post -2.24 EPS for the current year.
Insider Activity at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,964 shares of company stock valued at $20,622,925. 1.50% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of ALNY. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $61,160,000. Strategic Financial Concepts LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth $41,529,000. Eventide Asset Management LLC lifted its stake in Alnylam Pharmaceuticals by 157.9% during the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after buying an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC grew its position in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares in the last quarter. Finally, Telemark Asset Management LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at $27,503,000. 92.97% of the stock is owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Read More
- Five stocks we like better than Alnylam Pharmaceuticals
- What is Put Option Volume?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Expert Stock Trading Psychology Tips
- 3 Steel Stocks Soaring After Tariff Announcements
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.